Rani Therapeutics Holdings annual free cash flow
2020
2021
2022
2023
2024
2025
Rani Therapeutics Holdings Free Cash Flow (FCF) History (RANI)
Rani Therapeutics Holdings reported −$18.8M in free cash flow for fiscal 2025, an increase of $17.0M from the previous fiscal year, with a free cash flow margin of −1151.38%.
View full Rani Therapeutics Holdings company overviewRani Therapeutics Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$18.8M | $17.0M | — | −1151.38% |
| 2024 | 2024-12-31 | −$35.8M | $16.7M | — | −3478.99% |
| 2023 | 2023-12-31 | −$52.5M | −$4.3M | — | — |
| 2022 | 2022-12-31 | −$48.1M | −$15.4M | — | — |
| 2021 | 2021-12-31 | −$32.8M | −$16.6M | — | −1205.41% |
| 2020 | 2020-12-31 | −$16.2M | — | — | −3497.84% |
Rani Therapeutics Holdings quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$9.1M | −$3.2M | — | −530.33% |
| Q1 2026 | 2026-03-31 | −$6.5M | $1.7M | — | −381.26% |
| Q4 2025 | 2025-12-31 | $294,000 | $9.0M | — | +20.12% |
| Q3 2025 | 2025-09-30 | −$5.1M | $3.5M | — | — |
| Q2 2025 | 2025-06-30 | −$5.8M | $3.3M | — | — |
| Q1 2025 | 2025-03-31 | −$8.2M | $1.2M | — | −4767.44% |
| Q4 2024 | 2024-12-31 | −$8.7M | $4.0M | — | −844.94% |
| Q3 2024 | 2024-09-30 | −$8.5M | $6.2M | — | — |
| Q2 2024 | 2024-06-30 | −$9.1M | $3.5M | — | — |
| Q1 2024 | 2024-03-31 | −$9.4M | $3.0M | — | — |
| Q4 2023 | 2023-12-31 | −$12.6M | $2.5M | — | — |
| Q3 2023 | 2023-09-30 | −$14.8M | −$2.1M | — | — |
| Q2 2023 | 2023-06-30 | −$12.6M | −$1.9M | — | — |
| Q1 2023 | 2023-03-31 | −$12.4M | −$2.8M | — | — |
| Q4 2022 | 2022-12-31 | −$15.2M | −$3.4M | — | — |
| Q3 2022 | 2022-09-30 | −$12.7M | −$1.5M | — | — |
| Q2 2022 | 2022-06-30 | −$10.7M | −$4.9M | — | — |
| Q1 2022 | 2022-03-31 | −$9.6M | −$5.5M | — | — |
| Q4 2021 | 2021-12-31 | −$11.7M | −$12.4M | — | — |
| Q3 2021 | 2021-09-30 | −$11.1M | — | — | — |
| Q2 2021 | 2021-06-30 | −$5.8M | — | — | −293.93% |
| Q1 2021 | 2021-03-31 | −$4.1M | — | — | −548.54% |
| Q3 2020 | 2020-09-30 | $670,000 | — | — | +620.37% |
Rani Therapeutics Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$16.2M to −$18.8M, a net decrease of $2.6M. Rani Therapeutics Holdings's latest reported quarter, Q2 2026, generated −$9.1M in free cash flow, a decrease of $3.2M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Rani Therapeutics Holdings filings at SEC.gov ↗